Trial Profile
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Oct 2021
Price :
$35
*
At a glance
- Drugs Tabalumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eli Lilly and Company
- 14 Nov 2012 Results presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 20 Mar 2012 Planned number of patients changed from 160 to 236 and additional location (Austria) added as reported by European Clinical Trials Database record.
- 02 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.